TI 061
Alternative Names: TI-061Latest Information Update: 05 Oct 2020
At a glance
- Originator Tioma Therapeutics
 - Developer Arch Oncology
 - Class Antineoplastics; Immunotherapies; Monoclonal antibodies
 - Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- No development reported Solid tumours
 
Most Recent Events
- 05 Oct 2020 No development reported - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease) in United Kingdom (IV) (Arch Oncology Website, October 2020)
 - 05 Oct 2020 No development reported - Phase-I/II for Solid tumours (Late-stage disease, Monotherapy) in United Kingdom (IV) (Arch Oncology Website, October 2020)
 - 23 Jan 2018 Tioma Therapeutics is now called Arch Oncology